Daily FNArena News - Australia

All | Australia | Book Reviews | Commodities | ESG Focus | FYI | International | Small Caps | SMSFundamentals | Technicals | Treasure Chest

Previous Stories

More Upside For Property Trusts

Aug 09 2012

Australian REITs have outperformed the market so far this year and brokers see scope for such outperformance to continue. Preferred sector exposures have been updated prior to profit season.


Bradken Delivers

Aug 08 2012

Full year earnings for Bradken met market expectations and with brokers continuing to forecast solid earnings growth in coming years, Buy ratings dominate for the stock.


CORRECTION: Lamp Going Out For Lynas?

Aug 07 2012

The decision to build a processing plant in Malaysia to save money may yet prove a disastrous one for Lynas, and a more than significant blow to the company’s rare earth aspirations.


Guidance The Key For Engineers & Contractors

Aug 07 2012

Outlook commentary accompanying upcoming engineering and construction company results is seen as a key for stocks in the sector as brokers update their preferred exposures.


Silex Cleaning Up

Aug 02 2012

Silex offers technology in the uranium enrichment, solar power and electronic chip markets and upside potential sees Bell Potter initiate coverage with a Buy rating.


Gloss Comes Off The Campbells

Aug 02 2012

A slowdown in junior mining company exploration has seen Campbell Brothers offer conservative earnings guidance, which has resulted in reductions to earnings forecasts and price targets.


Newcrest Surprises With No Surprises

Jul 27 2012

One upgrade for Newcrest and now it’s a full set of Buy ratings in the FNArena database, following a production report actually meeting expectations.


US Unemployment: Neither Natural Or Unnatural

Jul 27 2012

In the view of economics academics, US unemployment is being impacted by the nature of the current economic crisis but can recover without a rise in inflation.


Oil Search Shows How It’s Done

Jul 25 2012

Oil Search delivered a strong production result in the June quarter and with a nummber of potential catalysts in place brokers have reiterated Buy ratings on the stock.


Mesoblast Delivers Positive Early Results

Jul 25 2012

Mesoblast has delivered positive results in animal testing of a compound for treating rheumatoid arthritis, though brokers concede further work needs to be done.



Analyse The Market From A Different Angle